It’s here, download it now!

The latest insights from Vizient pharmacy experts to help you plan, budget and prepare for this critical time in our industry. As a member, you get exclusive access to the comprehensive report to shape your response to the pandemic.

Download report

3.09%

Projected drug price inflation rate
for July 1, 2022-June 30, 2023

Vizient experts take a deeper dive in defining “specialty” revealing that specialty retail is outpacing specialty infusion.

3.37%

Specialty pharmaceuticals
Projected drug price inflation rate

2.68%

Infusion/clinic price change

4.28%

Retail price change

Expert insights to empower pharmacy planning

Pharmacy Market Outlook Summer 2022 webinar
July 27, 2022 | 1:00 pm CT

In our next informational webinar series, our experts explore topics such as the increase in biosimilar competition, therapeutic advancement in cardiology and the continued impact of COVID-19.

Register now

2022 Top 5 areas of focus for healthcare executives

  1. Ending drug shortages and ensuring supply chain resilience
  2. Maximizing the biosimilar opportunity
  3. Aligning pharmacy with other critical stakeholders, including payers
  4. Collaborating on advocacy efforts related to 340B, user fee acts and other issues
  5. Amplifying the non-acute footprint

Top drugs by total member spend

  1. Remdesivir
  2. Adalimumab
  3. Pembrolizumab
  4. Ustekinumab
  5. Ocrelizumab

COVID-19 drug outpaces former front-runner, Humira, as number one drug by spend

Humira is no longer the top drug by spend, surpassed by Veklury, approved for the treatment of COVID-19 in 2020. While spend on Humira increased, hospitals spent even more on Veklury. With the anticipated patent expiration of Humira expected in 2023, will we soon see a tipping point?

Acute care antimicrobial spend decreases

Decreases in acute care visits and increase in non-acute ambulatory care, as well as increase in telehealth have impacted anti-microbial spend.

Total Infectious disease spend (excluding vaccines)
Percent market share of rituximab, trastuzumab, and bevacizumab (generic) products through Sept. 2021

Checkpoint inhibitors lead in oncology spend

With more indications and accelerated approvals, checkpoint inhibitors are outpacing traditional oncology treatments. Pembrolizumab alone made up 12.6% of Vizient member spend (Oct 2020-Sep 2021).

48% of FDA additional indication approvals given to checkpoint inhibitors, the fastest growing category by spend.

3.92%

Projected inflation rate

4.17%

Portion of drug spend

Moving pharmacy forward

Customized Oncology insights

Receive your customized view of oncology sub-service lines by spend and utilization with the Oncology Market Outlook.

Contact us to learn more

Let’s end drug shortages together

Learn how our newest program, Novaplus Enhanced Supply Reserve is making an impact on drug shortages and join the End Drug Shortages Alliance to be a part of the supply chain community driving transparency, quality, and access to additional production of essential medications.

Learn more

Connect with our pharmacy experts. We are here to support you.